[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582432":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":122,"collaborators":21,"id":124,"slug":21,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":21,"eligibilityCriteria":129,"healthyVolunteers":125,"sex":130,"minAge":131,"maxAge":21,"enrollmentInfo":132,"targetDuration":21,"studyType":135,"phases":136,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":43,"whyStopped":21,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with Metastatic non-small cell lung cancer (NSCLC)","EXPERIMENTAL","Participants will have a diagnosis of metastatic non-small cell lung cancer (NSCLC)",[13,14],"Drug: Zirconium Zr 89 crefmirlimab berdoxam","Diagnostic Test: PET\u002FCT Scan",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Zirconium Zr 89 crefmirlimab berdoxam","Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DIAGNOSTIC_TEST","PET\u002FCT Scan","Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET\u002FCT 24 hours later (+\u002F- 3 hours).",[9],[28],{"name":29,"affiliation":5,"role":30},"Adam Schoenfeld, MD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","646-608-4042","schoenfa@mskcc.org",{"name":37,"role":33,"phone":38,"phoneExt":21,"email":39},"Alexander Shoushtari, MD","646-888-4161","shoushta@mskcc.org",[41,56,67,78,90,101,111],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Memorial Sloan Kettering at Basking Ridge (Consent Only)","RECRUITING","Basking Ridge","New Jersey","07920","United States",{"type":49,"coordinates":50},"Point",[51,52],-74.54932,40.70621,{"lat":52,"lon":51},[55],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":57,"status":43,"city":58,"state":45,"zip":59,"country":47,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Memorial Sloan Kettering Monmouth (Consent Only)","Middletown","07748",{"type":49,"coordinates":61},[62,63],-74.11709,40.39428,{"lat":63,"lon":62},[66],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":68,"status":43,"city":69,"state":45,"zip":70,"country":47,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Memorial Sloan Kettering Bergen (Consent Only)","Montvale","07645",{"type":49,"coordinates":72},[73,74],-74.02292,41.04676,{"lat":74,"lon":73},[77],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":79,"status":43,"city":80,"state":81,"zip":82,"country":47,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)","Commack","New York","11725",{"type":49,"coordinates":84},[85,86],-73.29289,40.84288,{"lat":86,"lon":85},[89],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":91,"status":43,"city":92,"state":81,"zip":93,"country":47,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Memorial Sloan Kettering Westchester (Consent only)","Harrison","10604",{"type":49,"coordinates":95},[96,97],-73.71263,40.96899,{"lat":97,"lon":96},[100],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":102,"status":43,"city":81,"state":81,"zip":103,"country":47,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Memorial Sloan Kettering Cancer Center (All protocol activities)","10065",{"type":49,"coordinates":105},[106,107],-74.00597,40.71427,{"lat":107,"lon":106},[110],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":112,"status":43,"city":113,"state":81,"zip":114,"country":47,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)","Uniondale","11553",{"type":49,"coordinates":116},[117,118],-73.59291,40.70038,{"lat":118,"lon":117},[121],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"type":123,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100582432",false,"NCT06863233","A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer","Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging","Inclusion Criteria:\n\n* Patient must be 18 years of age or older at the time of signing the informed consent.\n* Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer\n* Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.\n* Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.\n* Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)","ALL","18 Years",{"count":133,"type":134},5,"ESTIMATED","INTERVENTIONAL",[137],"PHASE1","The purpose of this study to learn whether PET\u002FCT (positron emission tomography\u002Fcomputed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells",[140,141,142],"Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer",[140,141,142,5,144],"24-369","2025-08-11",{"date":147,"type":148},"2025-08-12","ACTUAL",{"date":150,"type":148},"2025-03-03",{"date":152,"type":134},"2028-03-03",{"name":5,"class":6},7]